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Tumor Induction of VEGF Promoter Activity
in Stromal Cells
culture express significant levels of at least onepolypep-
tide mitogenic for endothelial cells, including vascular
endothelial growth factor/vascular permeability factor
Dai Fukumura,1,7 Ramnik Xavier,2,5,7
Takeyuki Sugiura,5 Yi Chen,1
Eun-Chung Park,3 Naifang Lu,5
Martin Selig,4 Gunnlaugur Nielsen,4 (Ferrara and Davis-Smyth, 1997), basic fibroblast growth
factor (bFGF), and other cytokines that promote endo-Tatyana Taksir,4 Rakesh K. Jain,1,6
and Brian Seed5,6 thelial cell proliferation (Fidler, 1995; Friesel and Maciag,
1995).1Edwin L. Steele Laboratory
Department of Radiation Oncology As the neoplastic cells of solid tumors proliferate, they
develop a complex association with the surrounding2Gastrointestinal Unit
3Melvin B. and Barbara K. Nessel nonneoplastic tissue that is suggestive of an abnormal
genesis of solid tissue with its associated matrix, tissueGene Therapy Center
4Department of Pathology stromal cells, and vascular supply (Dvorak et al., 1995).
Similarities between the stroma of tumors and wounds5Department of Molecular Biology
Massachusetts General Hospital has led to the suggestion that tumors can be thought
of as wounds that do not heal (Dvorak, 1986). At presentBoston, Massachusetts 02114
the factors that regulate the development of the nonma-
lignant constituents of tumors, as well as the influences
these constituents exert on the neoplastic compart-Summary
ment, are poorly understood (Helmlinger et al., 1997;
Jain, 1997). In large measure the scarcity of informationWe have establisheda line of transgenic mice express-
about the regulatory circuits that control the interplaying the A. victoria green fluorescent protein (GFP) un-
between tumor and stroma can be attributed to theder thecontrol of the promoter for vascular endothelial
difficulty of simulating the tumor microenvironment ingrowth factor (VEGF). Mice bearing the transgene show
vitro.green cellular fluorescence around the healing mar-
To begin to study the interactions that lead to tumorgins and throughout the granulation tissue of superfi-
angiogenesis, we have created and analyzed transgeniccial ulcerative wounds. Implantation of solid tumors
mice that express an engineered version of GFP underin the transgenic mice leads to an accumulation of
the control of the human VEGF promoter. In these micegreen fluorescence resulting from tumor induction of
VEGF promoter activation associated with normal woundhost VEGF promoter activity. With time, the fluores-
repair is manifested by fluorescence developing at thecent cells invade the tumor and can be seen through-
wound margins and extending throughout the granula-out the tumor mass. Spontaneous mammary tumors
tion tissue. Following implantation of solid tumors,induced by oncogene expression in the VEGF-GFP
intensely fluorescent fibroblasts can be observed sur-mouse show strong stromal, but not tumor,expression
rounding and infiltrating the tumor mass. When sponta-of GFP. In both wound and tumor models the predomi-
neous mammary tumors in the VEGF-GFP backgroundnantGFP-positive cells are fibroblasts. The finding that
are examined, GFP can be found in fibroblasts sur-the VEGF promoter of nontransformed cells is strongly
rounding the neoplastic nodules but not in the tumoractivated by the tumor microenvironment points to a
cells themselves.need to analyze and understand stromal cell collabo-
ration in tumor angiogenesis.
Results
Introduction
A reporter for VEGF promoter activity was prepared in
The neovascularization of solid tumors facilitates their which an engineered GFP was placed immediately
growth and metastasis by providing nutrient flow and a downstream of 2.85 kb of VEGF promoter and 59 un-
frequently incomplete, fenestrated endothelial barrier translated region. To reduce integration site depen-
between neoplastic cells and circulation (Fidler, 1995; dence the transcription unit was inserted between tan-
Hanahan and Folkman, 1996; Jain, 1997). The new blood dem copies of the core AT-rich element of the matrix
vessels that develop within solid tumors are thought to attachment region located 39 to the human beta globin
arise as a result of the proliferation and migration of locus. Three pups surviving to maturity were found to
endothelial cells from existing vasculature supplying the be transgenic by analysis of DNA prepared from tail
tumor bed in a complex process that involves the regu- sections and were tested for acquisition of green fluo-
lated interaction of several soluble mediators and their rescence around the margins of a lesion generated by
cognate receptors (Hanahan, 1997; Risau, 1997). Al- a small full-thickness wound of one ear. All three animals
though the mechanisms by which endothelial cells are showed similar responses, but the signal was weak in
recruited to the tumor are not completely understood, two. The mouse with the best response was then mated
it is well documented that virtually all malignant cells in to generate the transgenic line.
Figures 1a and 1b show transmission and fluores-
cence images obtained by intravital microscopy of a6 To whom correspondence should be addressed.
7 These authors contributed equally to this work. healing full-thickness circular incision in the ear of the
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Figure 1. VEGF Promoter Activity during Wound Healing in Transgenic Mice
(a±c) Low power microscopic images of a full-thickness wound in the ear of VEGF-GFP transgenic founder 2 weeks after the wound creation.
Transillumination (a) and GFP fluorescence (b and c) images were either photographed (a and b) with ASA 400 film or acquired with the aid
of an intensified CCD camera (c). (c) is shown to illustrate the relative intensities of signal observed with the CCD camera and conventional
film.
All subsequent images (d±i) were recorded digitally and represent GFP expression during wound healing of VEGF-GFP transgenic mice (FVB-
C3H F1 hybrid) 1 week (d and g), 2 weeks (e and h), and 3 weeks (f and i) after wound creation. The fluorescence images were digitized and
processed at the same instrument settings. One week after the wound creation, weak GFP fluorescence was observed predominantly at the
margins of the wound (d and g). Only a few newly formed vessels can be seen localized at the periphery of the wound. Two weeks after
wound creation, the GFP fluorescence is brighter and more localized toward the center of the wound (b, c, e, and h). Angiogenesis can be
observed in the wound, especially in the peripheral region (a). Three weeks after the wound creation, GFP fluorescence is further increased
and advanced toward the center of the wound (f and i). The bar (a) represents 500 mm, and the same scale applies to all panels.
founder mouse. Around the incision margins can be Two weeks after wound creation, the GFP fluorescence
was brighter and had advanced toward the center ofseen distinct green fluorescence arising from local acti-
vation of the reportergene in response towound-elicited the wound (Figures 1b, 1c, 1e, and 1h). More prominant
angiogenesis was observed at this time, especially at thefactors. The color images shown in Figure 1 were ac-
quired at day 14 postwounding. In the first few days wound periphery (Figure 1a). Three weeks after wound
creation, GFP fluorescence was further increased andafter wound creation a thick scab was observed on the
wound. Because the scab showed significant autofluo- had continued to advance toward the center of the
wound. Observation was discontinued before the ulcersrescence, it was difficult to observe GFP-specific fluo-
rescence while it was present. The scab disappeared that formed at the wound site had completely healed.
GFP is a sensitive reporter because it is easily de-about 1 week after wound creation, and the wound was
then seen to be partially filled in with granulation tissue. tected, cell-restricted, and stable. The fluorescence in-
tensity of cells expressing the GFP reporter is a convolu-Two examples of the characteristic time course of GFP
expression following full-thickness wounds in founder tion of transcript creation with the decay functions for
both mRNA and protein over the natural lifetime of GFPprogeny are shown in the lower panels of Figure 1. Weak
GFP fluorescence was observed predominantly at the in vivo. To estimate the relevant parameters, we trans-
fected cells of the U87 (human glioma) and LS174T (hu-margins of the wound 1 week after wound creation (Fig-
ures 1d and 1g). Only a few newly formed vessels could man colon adenocarcinoma) cell lines with a construct
bearing the GFP expression cassette described abovebe seen, localized at the wound periphery (not shown).
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hepatocellular carcinoma HCaI, were implanted subcu-
taneously in dorsal skin chambers attached to trans-
genic F1 hybrids. Although the distribution and time
course of fluorescence are different for the two tumors,
fluorescence generally first appears at the margins (Fig-
ures 3b, 3c, 3e, and 3h) and penetrates into the tumor
mass (Figures 3f, 3i, and 3l). In the mammary carcinoma,
strong fluorescence can often be seen retained about
the periphery (e.g., Figure 3c). Dense vascularization
occasionally limits fluorescence detection (Figure 3l).
Over a longer period of time, the mammary carcinoma
organizes and evolves along a somewhat different path
than the hepatoma (Figure 4). Although initially the fluo-
rescent cellsare seen exclusively at the tumor periphery,
the fluorescent cells appear to penetrate quickly into
the HCaI tumors. An example of fluorescence flare dur-
ing the establishment of such a tumor is shown in the
bottom row of Figure 4. In this sequence a period of
intense fluorescence is followed by a diminution of sig-
nal intensity as neovasculature appears. It seems likelyFigure 2. GFP Turnover in Mammalian Cells in Culture
that this progression reflects a local oxygen and/or nutri-
Total fluorescence at 510 nm of lysates prepared from U87 (human
ent demand that subsides as the need for vasculatureglioma) and LS174T (human colon adenocarcinoma) cells trans-
is satisfied. Whatever the cause, dense vascularizationfected with GFP under the control of a tetracycline-sensitive pro-
ensues and the signal drops quickly (compare 4i and 4lmoter. At time 0, tetracycline was added to inactivate the promoter.
The ratio of the fluorescence intensity I to the initial fluorescence with 4h and 4k). In contrast, the MCaIV tumors in this
intensity I0 is shown. The lines fit to the data were generated by a series continued to show intense fibrous fluorescence
linear least squares regression and are satisfied by the equations that came to colocalize with vascular bundles (Figure
I/I0 5 1.209e20.468t and I/I0 5 1.402e20.818t (t in days), corresponding 4c and 4f).
to GFP terminal half-lives of 1.48 and 1.18 days in U87 and LS174T
Because contributions from fluorescence sources outcells, respectively.
of the focal plane make it difficult to distinguish cell
shapes with precision, intravital confocal microscopy was
undertaken. Using this approach, out-of-plane signalunder the control of a synthetic tetracycline-responsive
was greatly reduced, and similar patterns of cellular fluo-promoter (Gossen and Bujard, 1992). Following growth
rescence could be seen around the margins of 3-week-in culture under conditions in which the GFP was fully
old wounds or within implanted tumors 3 weeks postim-induced, tetracycline was added to the medium to inacti-
plantation (Figure 5). Imaging of the tumor and wound
vate the promoter, and the total fluorescence activity of
at higher magnification showed that individual cells
the culture was determined at various times thereafter.
could be detected throughout the tumor mass. In both
The recorded values thus provide a measure of fluores-
cases the fluorescent cells had the extended morphol-
cence independent of cell proliferation and, hence, inde- ogy that is characteristic of tissue fibroblasts (Figure 5).
pendent of dilution effects attributable to increases in Histologic examination of the implanted breast carci-
cell size or number. Figure 2 shows that the fluorescence noma and hepatocellular carcinoma at 1 week showed
of lysates prepared from the two transfected cell types tumor nodules surrounded by fibroblastic proliferation
declined with terminal half-lives of 35.5 hr and 28.3 hr for with no extension into the tumor nodules (Figures 6a
U87 and LS174T, respectively. The ordinate intercepts and 6f). The rim of fibroblast proliferation was in the
were greater than unity in both cases, consistent with region seen to be extensively populated with green fluo-
a delay between removal of tetracycline and initiation rescent cells by confocal microscopy. Consistent with
of decay that was in strikingly good agreement between this, the fibroblasts from this portion of the section were
the two cell lines, 9.6 hr for U87 and 9.8 hr for LS174T. positive on immunohistochemical staining with a poly-
Assuming that this lag represents the effective interval clonal anti-GFP antibody (Figure 6e). At 3 weeks, the
for termination of production (i.e., assimilates the time fibroblasts can be seen to extend from the periphery
required for both cessation of promoter activity and into the tumor bed, forming fibrous septae (Figures 6b-
decay of mRNA), GFP in mammalian cells in culture has 6d). Examination of the skin wound showed fibroblastic
an estimated half-life of between 1.2 and 1.5 days. If proliferation underneath the ulcer that fills the wound
similar characteristics are applicable to cells in vivo, bed at 3 weeks (Figure 6g). No reepithelialization is pres-
the observed GFP intensity in the photomicrographs ent 1 week after wounding, and the fibroblasts adjacent
represents the integral of promoter activityover a natural to and beneath the wound show strong GFP immunore-
(exponential) decay interval of approximately 2 days. activity (Figure 6h). GFP-positive cells in tumor sections
To evaluate VEGF promoter activity in the context of did not stain positive for CD31, a marker of small vessel
tumor development, we produced hybrid mice by mating endothelium, nor for CD45 (pan-hematopoietic cell), nor
FVB-derived, VEGF-GFP transgenic animals with wild- CD3 (T-lymphoid cell) markers (not shown). On Giemsa
type C3H mice. The resulting animals can serve as hosts staining the few cells found to stain metachromatically
for well-studied C3H-derived tumor lines. Tumors from were round to oval in shape, consistent with an identifi-
cation as tissue mast cells. These cells were far lesstwo such lines, the mammary carcinoma MCaIV and the
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Figure 3. GFP Reporter Activity in Tumors Implanted in VEGF-GFP Transgenic Mice
Photomicrographs of MCaIV, a murine mammary carcinoma (a±f) and HCaI, a murine hepatoma (g±l), grown in dorsal skin chambers of VEGF-
GFP transgenic mice. The left panels (a, d, g, and j) are transilluminated images at 1 week after tumor implantation, and the middle and right
panels are the corresponding fluorescence images at 1 week (b, e, h, and k) and 2 weeks (c, f, i, and l) after the tumor implantation. One week
after tumor implantation, marked vessel dilatation was observed in the host vessels surrounding or underneath the tumor xenografts (a and
d). GFP fluorescence was initially localized at the tumor-host interface of HCaI tumors (h and k). Two weeks after the tumor implantation, the
GFP fluorescence was intensified (c and d) and expanded (i and l). The vasculature in the tumor became apparent at this point. In general,
the peripheral region of the tumor (tumor-host interface) shows stronger GFP fluorescence than the center. The bar in (a) represents 500 mm,
and the same scale is used in all panels.
numerous than the fibroblasts. To make a definitive iden- Examination of wound and tumor specimens at 2 weeks
(Figures 7d-7h) also showed proliferation of fibroblasts.tification of the stromal cells, we prepared sections for
electron microscopy (Figure 6i). In these specimens the fibroblasts are more mature,
containing abundant dilated and undilated rough endo-Ultrastructural examination of the 1 week tumor speci-
men (Figure 7a-7c) revealed proliferation of spindle- plasmic reticulum and fewer ribosomes. The extracellu-
lar matrix contains more collagen fibers that are beingshaped cells adjacent to cohesive nests of tumor cells.
The spindle-shaped cells have the features of primitive secreted by the fibroblasts (Figures 7f and 7h). The spin-
dle-shaped cells didnot show intracytoplasmic granulesfibroblasts, containing abundant intracytoplasmic ribo-
somes, rough endoplasmic reticulum, few mitochondria, and bore no prominent intracytoplasmic ribosomes,
characteristic of mast cells/histiocytes and lymphoidand pinocytotic vesicles (Figure 7b and 7c). They are
arranged individually and enmeshed within a matrix con- cells, respectively.
To compare in vivo and in vitro properties, primarytaining occasional banded collagen-dilated fibers.
Tumor Activation of Stromal VEGF Promoter
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Figure 4. Time Course of GFP Expression during Tumor Growth in the VEGF-GFP Transgenic Mice
GFP fluorescence images of MCaIV tumors (a±f) and HCaI tumors (g±l) were acquired with a digital camera. Data were acquired under identical
conditions in all panels. The left panels (a, d, g, and j), the middle panels (b, e, h, and k), and the right panels (c, f, i, and l) represent the same
tumor at 1 week, 2 weeks, and 3 weeks after implantation, respectively. GFP fluorescence was generally more intense at the tumor periphery.
Note the high degree of correlation between fluorescence and vasculature in (c) and (f). (i) and (l) show only a part of the tumor. The growth
rate and angiogenesis varied between individual tumors and tumor types. The bar in (a) represents 1 mm in all panels.
embryo fibroblasts were prepared from VEGF-GFP mice of experimental resolution, the VEGF promoter of fibro-
blasts in culture is induced as strongly as that of fibro-and propagated in culture. Flow cytometry of cells
grown in culture unexpectedly showed a bimodal pat- blasts infiltrating implanted tumors. Measurement of the
concentration of VEGF in the culture supernatant of fi-tern of constitutive GFP expression (Figure 8). The rela-
tive induction of the VEGF promoter under these condi- broblasts prepared from transgene-positive and -nega-
tive mice showed that the ratio of production by positivetions was determined by comparison of the signal
intensities observed in vitro and in vivo. Tumors im- cultures compared to negative cultures was 1.24 6 0.25
(n 5 4). Thus, there are no significant differences be-planted in the VEGF-GFP mouse were excised, dissoci-
ated, and subjected to flow cytometry. Although the cell tween the endogenous VEGF promoter activity of trans-
genic and nontransgenic fibroblasts. However, transgenicnumbers were small, the fluorescence distribution of
the cells recovered from the tumors coincided with the cultures tended to show a decrease in GFP frequency
with time, which may reflect a selection against cellsfluorescence distribution observed following cytometry
of primary cells in culture (Figure 8). Thus, to the limit expressing high levels of GFP.
Cell
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Figure 5. Confocal Microscopy of GFP Fluo-
rescence in Both Wound and Tumor in the
VEGF-GFP Transgenic Mice
GFP-positive cells were visualized by confo-
cal laser microscopy. Both the wound in the
ear (a and c) 3 weeks after the wound creation
and MCaIV tumor grown in the dorsal skin
chamber (b and d) 3 weeks after the tumor
implantation showed spindle-shaped fluo-
rescent cells.
The bar in (a) represents 200 mm, and the
same magnification is shown in (b); the bar
in (c) represents 50 mm, and the same magni-
fication is shown in (d).
Mice bearing the VEGF-GFP transgene were mated lived phenomenon in both the wounds and tumors stud-
with mice bearing the polyoma middle T antigen under ied here. Strong GFP production associated with prolif-
the control of the mouse mammary tumor virus long eration of mesenchymal elements could be seen for
terminal repeat promoter. Spontaneousmultifocal mam- weeks following wounding or tumor implantation. The
mary tumors have been shown to appear with high fre- distribution and evolution of fluorescence appeared to
quency in the lattermice (Guy et al., 1994). Mice transgenic follow a characteristic course for the two tumor types
for both the GFP and the middle T transgenes were studied. The mammary carcinoma developed a more
found to develop multiple spontaneous mammary tu- septated fluorescence that remained intense as the
mors at ages 4 to 5 months. The mice were sacrificed, tumor grew, whereas the hepatocellular carcinoma de-
and the lesions were examined for distribution of GFP veloped a diffuse fluorescence that waned as dense
by immunohistochemistry. In general the spontaneous vascularity ensued. Both tumor types showed extensive
tumors were similar in appearance and organization to penetration of fluorescent cells into the tumor mass.
the implanted MCaIV mammary carcinoma, with vascu- A similar picture was seen in the setting of spontane-
lar plexi apparent in the perineoplastic stroma. No anti- ous tumorigenesis ina transgenic oncogenemodel. GFP
GFP antibody reactivity was detected in the tumor nod- immunoreactivity was apparent around the margins of
ules themselves, which were relatively avascular (Figure multifocal tumor nodules. No GFP reactivity was detect-
9). In contrast the fibrotic tissue surrounding the nod- able in the nodules themselves, suggesting that VEGF
ules, which was hyperplastic and vascularized, showed
promoter activity in the neoplastic cells was at best
numerous scattered cells reactive with anti-GFP anti-
poorly induced. However, fibroblasts in the fibrotic tu-
body (Figure 9). Fibroblasts surrounding blood vessels
mor matrix were clearly positive for GFP.
traversing the stroma stained positive for GFP, whereas
Of the different mechanisms that regulate VEGF pro-
endothelial cells were negative (Figure 9).
moter strength, hypoxia (Shweiki et al., 1992) is best
understood. However, in vivo measurements have shownDiscussion
that the partial oxygen pressure (pO2) of tumor tissue
and vasculature is heterogeneous and vessel perfusionUnderstanding the factors that govern the growth and
rates do not necessarily correlate with local oxygenationmetastasis of solid tumors is an important but challeng-
(Helmlinger et al., 1997). Although malignant neoplasmsing objective. Much of the difficulty in understanding
can develop impressive vascularity, the vasculature istumor dynamics comes from the complexity of the ex-
imperfect, disordered and leaky, and poorly conductsperimental systems in vivo and from the failure of in
nutrients and erythrocytes through the tumor massvitro culture models to faithfully reflect events taking
(Jain, 1997). As a result the tumor shows irregular, con-place in an organismic context. In the studies reported
stantly changing patterns of metabolic demand that mayhere, intravital microscopy and a sensitive intracellular
be expected to induce cognate fluctuations in VEGFreporter have been exploited to increase our under-
transcriptional activity.standing of the interplay between neoplastic cells and
VEGF mRNA accumulation in vivo is also regulatedthe underlying stromal bed. Using a transgenic animal
by prolongation of mRNA half-life through posttran-line in which the VEGF promoter drives the expression
scriptional regulatory events mediated by specific cis-of GFP, we have been able to detect and track activation
sequences encoded in the mRNA 39 untranslated regionof the VEGF promoter in response to wounding and
(Shima et al., 1995; Stein et al., 1995; Levy et al., 1996;neoplasia.
VEGF transcriptional activation was a surprisingly long- Damert et al., 1997). Because the reporter construct
Tumor Activation of Stromal VEGF Promoter
721
Figure 6. Light Microscopy of Mammary Carcinoma and Hepatocellular Carcinoma in VEGF-GFP Transgenic Mice
(a) Breast tumor implant at 1 week showing fibroblast proliferation (top) surrounding a tumor nodule (H&E).
(b) Same tumor at 3 weeks showing extension of the peripheral fibroblastic proliferation into the tumor nodule, forming fibrous septae (H&E).
(c and d) Higher power of the septae that are formed by bland spindle-shaped fibroblasts surrounded by pink collagenous matrix (H&E).
(e) Immunohistochemical stain for green fluorescent protein shows positive (red) cytoplasmic staining of the fibroblasts. The surrounding
neoplastic cells are negative.
(f) Hepatocellular carcinoma implant after 1 week showing peripheral fibroblastic proliferation surrounding a tumor nodule. No extension of
the fibroblastic proliferation into the tumor is present at this stage (H&E).
(g) One micrometer section of skin with surface wound (right) and underlying fibroblastic proliferation.
(h) Immunohistochemical stain for GFP shows intense cytoplasmic staining of the fibroblasts within the ear wound.
(i) A 1 mm section better illustrates the neoplastic cells (3 week tumor, top) and surrounding fibroblastic proliferation (Toluidine blue). Note
marginal vessels with erythrocytes (blue).
described in this work does not contain the 39 untrans- culture conditions that mimic the status of normal (unac-
tivated) tissue in vivo.lated region, it does not assimilate mRNA stability ef-
fects. In normal rat primary fibroblasts grown in culture, hyp-
oxia induces a G0/G1 checkpoint that results in growthIn both normal wound recovery and neoplasia, the
most prominent cells showing VEGFpromoter activation arrest, whereas the same conditions cause transformed
fibroblasts to undergo apoptosis (Graeber et al., 1994;are spindle-shaped cells that ultrastructurally display
classic features of fibroblasts and do not show external Schmaltz et al., 1998). Because our findings point to a
potentially important role for fibroblasts inVEGF produc-lamina, junctions, tonofilaments, lumen formation, Wei-
bel-Palade bodies, or other structural features sugges- tion, the report that hypoxia induces growth arrest in
vitro is unexpected and further suggests the importancetive of keratinocyte or endothelial cells. The cells are
not sessile, but migrate into the wound or tumor, pre- of studying events in vivo. Similarly, the finding that
fibroblasts in culture show highly induced VEGF tran-sumably under the influence of as-yet-unidentified che-
motactic factors. Fibroblasts recovered from the tumor scriptional activity clearly indicates that other factors
than hypoxia can significantly affect promoter strength.mass and analyzed by flow cytometry have the same
fluorescence profiles as fibroblasts propagated in cul- VEGF is widely expressed in normal tissues (Berse et
al., 1992), and its promoter region bears many of theture. We conclude from this that fibroblasts grown under
standard conditions in vitro are as activated with respect characteristics of housekeeping genes (Tischer et al.,
1991). Hence, it seems likely that in principle almost anyto VEGF promoter activity as fibroblasts in tumors. This
rather surprising observation suggests that culture in cell type could serve as a source for VEGF upon hypoxic
or ischemic demand. In the context of wound angiogen-vitro is highly activating for VEGF promoter function and
that additional effort will need to be expended to find esis, previous studies have focused on the role of kera-
Cell
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Figure 7. Electron Microscopy of Tumor and
Wound Sections Showing High Fluorescence
(a) Tumor at 1 week. Low power showing
spindle-shaped fibroblasts adjacent to cohe-
sive nests of tumor cells (right and bottom).
(b and c) The fibroblasts have delicate cyto-
plasmic processes and contain abundant in-
tracytoplasmic ribosomes, rough endoplas-
mic reticulum, occasional mitochondria, and
pinocytic vesicles (brackets). Note the extra-
cellular collagen deposition (C) and and an
eosinophil (E) adjacent to the fibroblast.
(d) Ulcerative ear wound at 2 weeks. Fibro-
blasts with abundant rough endoplasmic re-
ticulum and peripheral filaments (*). A vessel
(V) is also present.
(e and f) Higher power showing abundant un-
dilated anddilated rough endoplasmic reticu-
lum (arrow). Surrounding the fibroblast are
collagen fibers (C) that cross the cell surface
and are being secreted by them.
(g) Mammary carcinoma at 2 weeks. Low
power view showing cohesive clusters of
neoplastic cells to the right (N) and discohe-
sive proliferation of fibroblasts to the left. A
vessel containing erythrocytes is present in
the lower left (V).
(h) The spindle-shaped fibroblasts are ar-
ranged individually and are enmeshed within
a matrix containing banded collagen fibers
(C). Their cytoplasm contains abundant rough
endoplasmic reticulum. Two capillary-sized
vessels are also present.
Final Magnifications: (a), 10003; (b), 16003;
(c), 25003; (d), 16003; (e), 30003; (f), 59003;
(g), 19003.
tinocytes. In culture these cells respond to growth fac- tissue can be attributed to fibroblasts. Although it is
likely that more superficial wounds would show ators and cytokines with increased VEGF production
(Frank et al., 1995),and shorter term studiesof epidermal greater keratinocyte involvement, it is significant that
the wounds in this study did not heal well and thatwounds using in situ hybridization have identified them
as a major source of VEGF transcripts (Brown et al., striking similarities were observed between the pattern
of induction of VEGF promoter activity in the wounds1992). The wounds created in this study were ulcerative
full-thickness excisions that generally showed little re- and implanted tumors, consistent with the earlier sug-
gestion that tumors behave as wounds that do not healepithelialization and healed poorly. Imaging of GFP fluo-
rescence during the period in which the keratinocyte (Dvorak, 1986).
At present the relative contributions of tumor andcontribution was previously reported to be dominant
(Brown et al., 1992) proved difficult because of the high stroma to endothelial cell proliferation and migration are
not understood. Although data from in vitro measure-level of autofluorescence associated with scab forma-
tion. During the later granulation phase, few of the fluo- ments of VEGF production by tumor cells in culture have
led to the assumption that the tumor is the principal ifrescent cells appeared to be epithelial in origin, and the
principal contribution to fluorescence in the granulation not sole source of VEGF, the results of this work point
Tumor Activation of Stromal VEGF Promoter
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Figure 8. Cytometry of VEGF-GFP Fibro-
blasts Propagated in Culture or Excised from
Tumors
Primary mouse embryo fibroblast cultures
were initiated from transgenic animals and
passaged in vitro. Cells analyzed by flow cy-
tometry were found to exhibit a bimodal fluo-
rescence distribution (left panel). Cells pre-
pared by digesting tumor samples with
collagenase and analyzing events in the scat-
ter gate corresponding to fibroblasts showed
a bimodal fluorescence pattern coincident
with that of cells grown inculture (right panel).
to the possibility that stromal elements play an important allows transformed cells to rapidly acquire resistance
to chemotherapeutic agents (Kerbel, 1991; Kim et al.,role. Mammary fibroblasts from both tumor and normal
1993; Fidler, 1995; Parangi et al., 1996; Boehm et al.,breast tissue have been shown to produce VEGF in
1997). A better understanding of stromal contributionsculture (Hlatky et al., 1994), and our findings indicate
will likely increase our awareness of the importance ofthat fibroblasts from other sources likely behave simi-
other molecules than VEGF in the growth of solid malig-larly. The finding that stromal fibroblasts penetrate deep
nancies and may result in the identification of new thera-into implanted tumors raises the need to consider
peutic targets for future treatments focusing on the tu-whether fibroblasts serve other functions besides pro-
mor stroma.duction of VEGF, possibly including the production of
chemotactic factors that elicit endothelial cell migration.
Experimental ProceduresIn addition, it is presently unclear what fraction of neo-
vascular growth can be attributed to VEGF as opposed Constructs and Reagents
to other polypeptides that have endothelial cell mito- Eight hundred base pairs of the core matrix attachment region from
genic potential, such as basic fibroblast growth factor. the human beta globin 39 DNaseI hypersensitive site (Fleenor and
Kaufman, 1993), comprising nucleotides 1601 to 2400 of GenBankTargeting antitumor therapy to stromal elements re-
X54282, were placed between MluI and SpeI sites upstream andquired for tumor growth may be a superior strategy for
between BamHI and NheI sites downstream of a GFP expression
retarding the growth of solid neoplasms, since normal vector consisting of a codon-optimized GFP bearing two mutations
tissue is unlikely to show the genetic plasticity that often (FS64LT) upstream of a human IgG1 intron andan SV40 polyadenyla-
tion sequence (Cormack et al., 1996; Haas et al., 1996; Heim andaccompanies malignant transformation, a plasticity that
Figure 9. Immunohistochemistry of GFP in Spontaneous Tumors Arising in VEGF-GFP Mice Bearing an MMTV-Py mT Transgene
VEGF-GFP mice expressing the polyoma middle T antigen under the control of the MMTV LTR develop multifocal spontaneous mammary
tumors (a±d). (a and b) Low power images showing positive reaction (red) with anti-GFP antibody by fibroblasts in the loose tumor stroma
but not in the tumor nodules.
(c and d) Higher power images of tumor/stroma interface. Note absence of detectable reactivity within the tumor cells.
(e) Blood vessel (arrows) in tumor stroma surrounded by GFP-positive fibroblasts. Within the vessel are a few polymorphonuclear leukocytes.
(f) Magnified view of (e). The endothelial cells lining the vessel (arrows) do not react with anti-GFP antibody.
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Tsien, 1996). VEGF promoter sequences from 552 to 3401 of Gen- Sections were stained by avidin biotin complex methods as de-
scribed previously (Cerf-Bensussan et al., 1983; Hollander et al.,Bank M63971 (Tischer et al., 1991) were inserted between SpeI and
HindIII to give the expression cassette. 1995). Tissue sections (4 mm) were air-dried for 10 min, fixed in
acetone, and air-dried again for 10 min. Sections were then incu-
bated in primary rabbit polyclonal antibodies to GFP (ClontechWound Preparation
1:100) for 1 hr. Secondary antibodies that were biotin- and cy3/5-Wounds were created using a modified technique previously de-
labeled were used to detect primary antibody staining for immuno-scribed (BondaÂ r et al., 1991). Mice were anesthetized with Ketamine
histochemistry and confocal microscopy, respectively. Each step90 mg/kg (Parke-Davis, Morris Plains, NJ) and Xylazine 9 mg/kg
was followed by three washes in phosphate-buffered saline. The(Fermenta, Kansas City, MO). Prior to excision, the overlying hair of
sections werethen incubated with ABC reagent, followed by postfix-the mouse ear was removed with a depilatory cream (Neet, Reckitt
ation in 2% paraformaldehyde, and counter stained with hema-and Colman Inc., Wayne, NJ). The dorsal skin layer of the ear, down
toxylin.to but not including the cartilage, was excised with microscissors
under a disecting microscope to provide a full-thickness wound of
approximately 2 mm in diameter. One, two, and three weeks after Electron Microscopy
wound creation, mice were anesthetized, the ears with the healing Tissues from four mice were processed for electron microscopy.
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